MAPK8 inhibitor AS601245 inhibited tumour size to 21% of DMSO treated control after 3 days (\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$p\ <\ 0.0001$$\end{document}p<0.0001, Dunnett’s multiple comparison test), while GW405833, which was the most neuroblastoma-selective inhibitor in vitro, reduced the tumour size to 75% of control (p = 0.0335, Dunnett’s multiple comparison test (Fig. 6e, f). Here, MAPK8 is linked to neuroblastoma.